Users of Diabetes Drug Mounjaro Lost More Weight Than Those on Ozempic, Large Study Finds

Users of Diabetes Drug Mounjaro Lost More Weight

Users of diabetes drug Mounjaro lost more weight, According to a new research of people taking the pharmaceuticals in the real world, overweight and obese adults who used the injectable medication Mounjaro lost more weight and were more likely to meet particular weight loss targets than people on a similar competitor, Ozempic.

Users of Diabetes Drug Mounjaro Lost More Weight

Users of Diabetes Drug Mounjaro Lost More WeightOzempic, or semaglutide, and Mounjaro, or tirzepatide, both imitate the effects of the gut hormone GLP-1, which promotes insulin secretion and inhibits food transit through the stomach. GLP-1 also sends messages to the brain, which aids with appetite regulation. Tirzepatide also activates a second gut hormone known as GIP, which may aid in its efficacy.

The medications are used to treat type 2 diabetes, but they have recently acquired appeal because they may help people shed significant amounts of weight.

The new study is a preprint, which means it has not yet been peer-reviewed or published in a professional journal. Its findings are consistent with clinical trial findings, and many clinicians assumed that tirzepatide was more effective after observing the effects in their diabetes patients.

However, there haven’t been many trials that compare the medicines side by side, particularly in those who don’t have diabetes. One such study is currently ongoing, although results are not expected until at least a year.

“Over 70% of American adults are overweight or obese, so there’s a huge potential for these medications to be used and [there’s] really a lack of information,” said Dr. Patricia Rodriguez, senior applied scientist at Truveta Research and main study author.

The study was not funded by any of the medicine companies. Instead, Truveta, a data analytics company owned and run by 30 US health care systems, launched it. Truveta aggregates anonymised patient records from these hospitals to solve research inquiries.

Weight Loss Medication Comparison

The US Food and Drug Administration has approved larger doses of tirzepatide and semaglutide for weight loss under the brand names Zepbound and Wegovy, respectively, because to their weight-loss benefits. The new study only looked at levels approved for the treatment of type 2 diabetes, which may limit its conclusions. The data was collected between May 2022 and September 2023.

Rodriguez and her colleagues went through hundreds of hospital records to identify overweight and obese persons climbing Mt. Kilimanjaro or Ozempic.

The study’s more than 18,000 participants had type 2 diabetes in just over half (52%). The remaining 48% had no history of diabetes noted in their medical records, thus researchers reasoned that this group of almost 9,000 patients was most likely taking the drugs off-label at the discretion of their doctor, primarily for weight loss.

People dropped more weight the longer they were on the medicine, although many stopped using it. Approximately half of those who participated in the study stopped using them during the study period.

The authors point out that it’s difficult to pinpoint why people stopped taking their prescriptions. Because both drugs in the trial were in short supply, they may have been difficult to get.

The most common side effects mentioned in medical records were nausea and vomiting, which were reported by around one in every five persons taking the drugs. Gallstones were reported in approximately 1 in every 6 people. The researchers highlight that the side effects of the drugs were quite similar, and there were no significant variations in the frequencies of any adverse event.

People lost more weight if they didn’t have diabetes, but even if they did, those on Mounjaro shed a higher percentage of their beginning weight than those on Ozempic.

At three months, the average weight loss for Mounjaro users was almost 6%, compared to nearly 4% for Ozempic users. The average weight decrease after six months on Mounjaro was 10%, compared to 6% on Ozempic.

At 12 months, participants on Mounjaro had lost an average of 15% of their body weight, compared to roughly 8% on Ozempic. Those discrepancies diminished after the researchers corrected their data for potential sources of bias.

The Most Effective is the One that Works

According to Dr. Mopelola Adeyemo, who treats people with diabetes and obesity at the University of California, Los Angeles, the study’s findings aren’t a major divergence from clinical trial outcomes.

According to Adeyemo, the ideal weight loss drug for an individual is the one that works for them. She has patients that cannot tolerate one type of GLP-1 drug, such as Ozempic or Mounjaro, but can tolerate another.

“I think there’s going to be roles for both of them, definitely, because both have been shown to not only help with weight loss but also diabetes and another cardiovascular benefits, as well,” Adeyemo said in a statement.

Novo Nordisk, which manufactures Ozempic for diabetes and Wegovy for weight loss, claims that the study is not a fair comparison.

“The doses of semaglutide evaluated in this analysis have not been investigated for chronic weight management, and there are no head-to-head trials that have reported which evaluate Wegovy and tirzepatide.” A representative for the FDA said in a statement.

When used for weight loss, semaglutide is taken at a greater dose, according to the firm.

“We agree completely,” Rodriguez stated. “We expect that in the obesity labelled medications, we would expect that people would lose more weight because the dosages are quite higher.”

The manufacturer of Mounjaro and Zepbound, Eli Lilly, has said that it does not support off-label use of their medications. It is requesting patience while it gathers more information.

“Our SURMOUNT-5 trial, which is a head-to-head trial comparing tirzepatide (Zepbound) and semaglutide (Wegovy) for the treatment of obesity or overweight with weight-related comorbidities, is expected to read out in 2025,” a company spokesman wrote in an email.

(2023 Cable News Network, Inc., a Time Warner Company. All intellectual property rights are reserved.)

Leave a Reply